References
- de Villiers TJ, Pines A, Panay N, et al. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 2013;16:316–37
- Williams JK, Anthony MS, Honoré EK, et al. Regression of atherosclerosis in female monkeys. Arterioscler Thromb Vasc Biol 1995;15:827–36
- Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomized trial. BMJ 2012; 345:e6409
- Hodis HN, Mack WJ. A ‘window of opportunity’: the reduction of coronary heart disease and total mortality with menopausal therapies is age- and time-dependent. Brain Res 2011;1379: 244–52
- Salpeter SR, Walsh JM, Greyber E., Ormiston TM, Salpeter EE. Mortality associated with HRT in younger and older women: a meta-analysis. J Gen Intern Med 2004;19: 791–804
- Whitmer RA, Quesenberry CP, Zhou J, Yaffe K. Timing of hormone therapy and dementia: the critical window theory revisited. Ann Neurol 2011;69:163–9
- Rocca WA, Grossardt BR, Shuster LT. Oophorectomy, menopause, estrogen treatment, and cognitive aging: clinical evidence for a window of opportunity. Brain Res 2011;1379:188–98
- Sarrel PM, Njike VY, Vinante V, Katz DL. The mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women aged 50 to 59 years. Am J Public Health 2013;103:1583–8
- Shapiro S, De Villiers TJ, Pines A, et al. Risks and benefits of hormone therapy: has medical dogma now been overturned? Climacteric 2014;17:215–22
- Shapiro S, de Villiers TJ, Pines A, et al. Re: Estrogen plus progestin and breast cancer incidence and mortality in the Women’s Health Initiative observational study. J Natl Cancer Inst 2014; 106:djt372
- Panay N, Fenton A. Has the time for the definitive, randomized, placebo-controlled HRT trial arrived? Climacteric 2011;14:195–6